Saturday, 31 October 2026European Markets

NORDIC SEMICONDUC Stock Bearish By 18% So Far On Thursday

Loading stream...

(VIANEWS) - Shares of NORDIC SEMICONDUC (Oslo Børs Benchmark Index_GI: NOD.OL) slid by a staggering 18.49% to kr120.15 at 11:36 EST on Thursday, following the last session's downward trend. Oslo Børs Benchmark Index_GI is dropping 0.44% to kr1,215.31, following the last session's downward trend. This seems, at the moment, a somewhat bearish trend exchanging session today.

NORDIC SEMICONDUC's last close was kr147.40, 24.41% below its 52-week high of kr195.00.

About NORDIC SEMICONDUC

Nordic Semiconductor ASA, a fabless semiconductor company, designs, sells, and delivers integrated circuits (ICs) and related products and services for use in short- and long- range wireless applications in Europe, the Americas, and the Asia/Pacific. The company offers bluetooth and multiprotocol Systems-on-Chip (SoCs) that provides short-range connectivity; and Systems-in-Package (SiPs), which offers connectivity on long-range LTE-M and NB-IoT cellular networks. It also provides nRF9160 SiP low power cellular IoT device, nRF Cloud solution, nRF Connect software development kit, and third-party cellular modules; DECT NR+, a non-cellular radio standard; nRF7002 Wi-Fi companion ICs; and nRF52840 and nRF5340 multiprotocol SoCs. In addition, the company offers Bluetooth mesh; Bluetooth direction finding solution; Bluetooth Low Energy SoCs; Bluetooth LE audio products; Matter, a Connected Home over IP solution; Thread, an IP-based wireless networking protocol solution; Zigbee products; ANT solutions, including wireless multiprotocol SoCs supporting the ANT wireless protocol; pre-certified development modules and modems; and range extenders. Further, it provides built-in power management on SoCs and dedicated power management ICs comprising nPM1100 PMIC, nPM1300 PMIC, nPM6001 PMIC, nPM1100 EK, and Power Profiler Kit II; Device-to-nRF Cloud and Cloud-to-nRF Cloud solutions; and application specific integrated circuits and related consulting services. The company's products are used in various applications, such as automotive, beacon, computer peripherals, connected health, connected home, education, industrial automation, LED lighting, logistics and transport, retail and payment, sports and fitness, toys and gaming, virtual reality and augmented reality products, and wearables. Nordic Semiconductor ASA was founded in 1983 and is headquartered in Trondheim, Norway.

Earnings Per Share

As for profitability, NORDIC SEMICONDUC has a trailing twelve months EPS of kr6.51.

PE Ratio

NORDIC SEMICONDUC has a trailing twelve months price to earnings ratio of 18.46. Meaning, the purchaser of the share is investing kr18.46 for every norwegian krone of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.49%.

Sales Growth

NORDIC SEMICONDUC's sales growth for the current quarter is negative 11.2%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.8%, now sitting on 776.73M for the twelve trailing months.

Growth Estimates Quarters

The company's growth estimates for the present quarter and the next is a negative 63.4% and a negative 42.9%, respectively.

More news about NORDIC SEMICONDUC (NOD.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com